429 related articles for article (PubMed ID: 24898159)
21. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
[TBL] [Abstract][Full Text] [Related]
22. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.
Lamy A; Gobet F; Laurent M; Blanchard F; Varin C; Moulin C; Andreou A; Frebourg T; Pfister C
J Urol; 2006 Dec; 176(6 Pt 1):2686-9. PubMed ID: 17085196
[TBL] [Abstract][Full Text] [Related]
23. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
[TBL] [Abstract][Full Text] [Related]
24. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.
Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828
[TBL] [Abstract][Full Text] [Related]
25. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.
Mhawech-Fauceglia P; Cheney RT; Fischer G; Beck A; Herrmann FR
Eur J Surg Oncol; 2006 Mar; 32(2):231-7. PubMed ID: 16412606
[TBL] [Abstract][Full Text] [Related]
26. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
[TBL] [Abstract][Full Text] [Related]
27. Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(-4-hydroxybutyl)nitrosamine.
Dunois-Lardé C; Levrel O; Brams A; Thiery JP; Radvanyi F
Mol Carcinog; 2005 Mar; 42(3):142-9. PubMed ID: 15690367
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic and Prognostic Implications of FGFR3
Geelvink M; Babmorad A; Maurer A; Stöhr R; Grimm T; Bach C; Knuechel R; Rose M; Gaisa NT
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30154342
[TBL] [Abstract][Full Text] [Related]
29. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder.
van Oers JM; Adam C; Denzinger S; Stoehr R; Bertz S; Zaak D; Stief C; Hofstaedter F; Zwarthoff EC; van der Kwast TH; Knuechel R; Hartmann A
Int J Cancer; 2006 Sep; 119(5):1212-5. PubMed ID: 16570285
[TBL] [Abstract][Full Text] [Related]
30. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.
Zuiverloon TC; van der Aa MN; van der Kwast TH; Steyerberg EW; Lingsma HF; Bangma CH; Zwarthoff EC
Clin Cancer Res; 2010 Jun; 16(11):3011-8. PubMed ID: 20404005
[TBL] [Abstract][Full Text] [Related]
31. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
Dienstmann R; Rodon J; Prat A; Perez-Garcia J; Adamo B; Felip E; Cortes J; Iafrate AJ; Nuciforo P; Tabernero J
Ann Oncol; 2014 Mar; 25(3):552-563. PubMed ID: 24265351
[TBL] [Abstract][Full Text] [Related]
32. Complexity of FGFR signalling in metastatic urothelial cancer.
Rodriguez-Vida A; Saggese M; Hughes S; Rudman S; Chowdhury S; Smith NR; Lawrence P; Rooney C; Dougherty B; Landers D; Kilgour E; Arkenau HT
J Hematol Oncol; 2015 Oct; 8():119. PubMed ID: 26497743
[TBL] [Abstract][Full Text] [Related]
33. FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer.
Theelen WS; Mittempergher L; Willems SM; Bosma AJ; Peters DD; van der Noort V; Japenga EJ; Peeters T; Koole K; Šuštić T; Blaauwgeers JL; van Noesel CJ; Bernards R; van den Heuvel MM
J Pathol Clin Res; 2016 Oct; 2(4):223-233. PubMed ID: 27785367
[TBL] [Abstract][Full Text] [Related]
34. Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor.
Zhou W; Du X; Song F; Zheng H; Chen K; Zhang W; Yang J
Oncotarget; 2016 Apr; 7(16):22234-44. PubMed ID: 26993773
[TBL] [Abstract][Full Text] [Related]
35. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
[TBL] [Abstract][Full Text] [Related]
36. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
van Oers JM; Zwarthoff EC; Rehman I; Azzouzi AR; Cussenot O; Meuth M; Hamdy FC; Catto JW
Eur Urol; 2009 Mar; 55(3):650-7. PubMed ID: 18584939
[TBL] [Abstract][Full Text] [Related]
37. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
[TBL] [Abstract][Full Text] [Related]
38. Description of a new mutation and characterization of FGFR1, FGFR2, and FGFR3 mutations among Brazilian patients with syndromic craniosynostoses.
Passos-Bueno MR; Sertié AL; Richieri-Costa A; Alonso LG; Zatz M; Alonso N; Brunoni D; Ribeiro SF
Am J Med Genet; 1998 Jul; 78(3):237-41. PubMed ID: 9677057
[TBL] [Abstract][Full Text] [Related]
39. Mutations of fibroblast growth factor receptor 3 gene (FGFR3) in transitional cell carcinoma of urinary bladder in Thai patients [Revision-2a].
Jantip J; Tanthanuch M; Kanngurn S; Karnchanawanichkul W; Pripatnanont C; Sangkhathat S; Thongsuksai P
J Med Assoc Thai; 2013 Aug; 96(8):976-83. PubMed ID: 23991606
[TBL] [Abstract][Full Text] [Related]
40. A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.
Neuzillet Y; Paoletti X; Ouerhani S; Mongiat-Artus P; Soliman H; de The H; Sibony M; Denoux Y; Molinie V; Herault A; Lepage ML; Maille P; Renou A; Vordos D; Abbou CC; Bakkar A; Asselain B; Kourda N; El Gaaied A; Leroy K; Laplanche A; Benhamou S; Lebret T; Allory Y; Radvanyi F
PLoS One; 2012; 7(12):e48993. PubMed ID: 23272046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]